

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

pET-28a(+):NL

RRID:Addgene_141289

Type: Plasmid

Proper Citation

RRID:Addgene_141289

Plasmid Information

URL: <http://www.addgene.org/141289>

Proper Citation: RRID:Addgene_141289

Insert Name: NLUC

Organism: Synthetic

Bacterial Resistance: Chloramphenicol and Kanamycin

Defining Citation: [PMID:31316580](#)

Vector Backbone Description: Backbone Marker:EMD Biosciences; Backbone Size:5369; Vector Backbone:pET-28 a (+); Vector Types:Bacterial Expression, Luciferase; Bacterial Resistance:Chloramphenicol and Kanamycin

Plasmid Name: pET-28a(+):NL

Relevant Mutation: Engineered for high stability ($t_{1/2}$ = 11.5 days at 37 °C) and codon optimised for expression in mammalian cells.

Record Creation Time: 20220422T221815+0000

Record Last Update: 20260815T080647+0000

Ratings and Alerts

No rating or validation information has been found for pET-28a(+):NL.

No alerts have been found for pET-28a(+):NL.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gosselin OJ, et al. (2026) Single-domain antibody inhibitors target the coiled coil arms of the *Bacillus subtilis* SMC complex. *eLife*, 15.

Zeng T, et al. (2025) ANXA1 binds and stabilizes EGFR to promote nasopharyngeal carcinoma radioresistance. *Molecular cancer therapeutics*.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. *Molecular therapy. Oncology*, 33(1), 200949.